Department of Internal Medicine, Creighton University Medical Center, Omaha, Nebraska, USA.
Biol Blood Marrow Transplant. 2013 Aug;19(8):1233-7. doi: 10.1016/j.bbmt.2013.05.019. Epub 2013 Jun 6.
Arrhythmias, especially supraventricular arrhythmias, often complicate the clinical course during autologous hematopoietic cell transplantation (AHCT). We wanted to determine the incidence and risk factors for cardiac arrhythmias during AHCT. The study included 983 patients (median age, 58 years [range, 19 to 77]; 61% male) who underwent AHCT between August 2006 and December 2010 at a single institution and for whom all relevant medical records were available for review. AHCT was done for plasma cell disorders in 58% patients and for lymphoma or leukemia in the remaining. Overall, 92 patients (9.4%) developed a supraventricular tachyarrhythmia at a median of 9 days posttransplantation (range, 0 to 18) and with a median duration of less than 1 day (range, <1 to 17 days). Atrial fibrillation was the most common and seen in 71 patients (7%), followed by atrial flutter and supraventricular tachycardia in 12 (1%) and 8 (1%) patients, respectively. In multivariate analysis, age older than 63 years, presence of premature supraventricular complexes or atrioventricular conduction delay on pretransplantation electrocardiogram, and history of any prior arrhythmia increased the risk of arrhythmia. Development of arrhythmia resulted in longer outpatient follow-up after AHCT, with the median follow-up for those developing an arrhythmia of 22 days compared with 19 days for the rest; P < .001. In conclusion, 9% of patients undergoing ASCT developed supraventricular arrhythmias posttransplantation, and this risk was elevated among older patients, those with a prior history of arrhythmias, and those with pretransplantation electrocardiographic abnormalities.
心律失常,尤其是室上性心律失常,常使自体造血细胞移植(AHCT)期间的临床过程复杂化。我们旨在确定 AHCT 期间发生心律失常的发生率和危险因素。该研究纳入了 983 例患者(中位年龄 58 岁[范围 19 至 77 岁];61%为男性),他们于 2006 年 8 月至 2010 年 12 月在一家机构接受了 AHCT,并且所有相关的病历都可用于审查。58%的患者接受 AHCT 是为了治疗浆细胞疾病,其余的则是为了治疗淋巴瘤或白血病。总体而言,92 例(9.4%)患者在移植后 9 天(范围 0 至 18 天)中位数时出现了室上性心动过速,并且中位持续时间不到 1 天(范围 <1 至 17 天)。心房颤动是最常见的,有 71 例(7%),其次是心房扑动和室上性心动过速,分别有 12 例(1%)和 8 例(1%)。多变量分析显示,年龄大于 63 岁、移植前心电图存在提前的室上性复合波或房室传导延迟,以及既往有任何心律失常史,增加了心律失常的风险。心律失常的发生导致 AHCT 后门诊随访时间延长,发生心律失常的患者中位随访时间为 22 天,而其余患者为 19 天;P<0.001。总之,9%接受 ASCT 的患者在移植后发生了室上性心律失常,并且这种风险在老年患者、有既往心律失常史的患者和存在移植前心电图异常的患者中升高。